






Breast Cancer

For diagnosis of almost all breast abnormal proliferations, especially breast carcinoma (BrCa), immunohistochemically it starts with the detection of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2) and Ki67 cell proliferation to differentiate the type of breast carcinomas. In general, breast carcinomas are classified into several different intrinsic subtypes including luminal A BrCa (ER+, PR+, HER2-, Ki67-), luminal B BrCa (ER+, PR+, HER2-, Ki67+), HER2 enriched BrCa (ER-, PR-, HER2+, Ki67+), normal-like BrCa (ER+, PR+, HER2-, Ki67-), and basal-like BrCa (ER-, PR-, HER2-, Ki67+, CK5/6+, EGFR+, triple negative breast carcinoma, TNBrCa). Ki-67 protein is associated with cell proliferation in which the increased expression of Ki-67 leads to a higher rate of cell division.




Estrogen Receptor (ER)

Cat. No: RMAB001, RMAB001-01, RMAB001-05, RMPD001

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: SP1

Estrogen receptor, Rabbit monoclonal antibody (clone SP1) IHC is an aid for assessing the breast cancer origin predicting the prognosis and outcomes of the breast carcinoma and directing patient management.




Progesterone Receptor (PR)

Cat. No: RMAB002, RMAB002-01, RMAB002-05, RMPD002

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: SP2

Progesterone receptor, Rabbit monoclonal antibody (clone SP2) IHC identifies the breast cancer origin and provides information of prognosis and management of the breast carcinoma.




Her2/neu (c-erbB-2)

Cat. No: RP006, RP006-01, RP006-05, PDR003

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: Rabbit

In about 15%-20% of patients with breast carcinoma Her2/neu (c-erbB-2/Oncoprotein) is overexpressed. Her2-positive breast cancer is highly invasive, prone to recurrence and metastasis.



Ki-67


Cat. No: RP026, RP026-01, RP026-05, PDR048

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: Rabbit

Ki-67 is a cell proliferation index marker. It has been proposed as a useful clinical marker for breast cancer subtype classification, prognosis, and prediction of therapeutic response.

GATA3 is a transcription factor involved in the differentiation of many tissue types including the breast luminal epithelial cells. GATA3 is a superior marker for ER+ breast carcinoma to Gross Cystic Disease Fluid Protein 15 (GCDFP-15) and Mammaglobin (MGB) with labelling consistently reported in over 90% of ER+breast carcinomas. In addition, GATA3 is sensitive for TNBrCa with labelling commonly reported in over 50% - 83% and has greater utility than GCDFP-15 and mammaglobin (MGB) in this context. GATA3 also displays nuclear rather than cytoplasmic labelling which can be easier to interpret and shows strong and diffuse labelling in nearly all ER+breast carcinomas. GATA3 labels T-lymphocytes which serve as useful internal controls in GATA3 negative tumors. GATA3 is not specific for breast carcinoma however, labels urothelial carcinomas, squamous cell carcinomas, and mesotheliomas with labelling in smaller numbers of pancreatic adenocarcinomas, lung adenocarcinomas, and others.




GATA3

Cat. No: Mob564, Mob564-01, Mob564-05, PDM564

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: L50-823

GATA3 has been reported to be expressed in all histologic subtypes of breast carcinoma such as invasive ductal carcinomas, micropapillary carcinomas, invasive lobular carcinomas, pleomorphic lobular carcinomas, mucinous carcinomas, and breast carcinomas with endocrine differentiation.




Mammaglobin A

Cat. No: RMAB036, RMAB036-01, RMAB036-05, RMPD036

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: EPR 9092

Mammaglobin-A is a mammary marker frequently used for diagnosis of breast carcinoma, primary as well as metastatic breast carcinoma whose primary origin cannot be easily identified.



GCDFP-15


Cat. No: Mob526, Mob526-01, Mob526-05, PDM261

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: DBM15.52

GCDFP-15 is an IHC marker frequently used to evaluate mammary differentiation in females and demonstrate a potential mammary origin of metastatic carcinoma of unknown primary origin.

About 15%-20% of breast carcinoma are characterized with carcinoma cells not being immunostained by antibodies against ER, PR, and Her2/neu (c-erbB-2/Oncoprotein) and referred as TNBrCa or basal-like breast carcinoma. TNBrCa usually has poorer prognosis and are associated with premenopausal African American women, BRCA1 mutations and higher propensity for brain metastases. IHC markers are often used for identifying basal-like breast carcinoma which include basal cytokeratin such as CK5, CK5/6, CK14, CK17 and EGFR. In particular, the positivity of CK5 and EGFR can be helpful in diagnosing ER-/PR-/HER2-, poorly differentiated or undifferentiated invasive carcinomas of the breast as TNBrCa, especially in the core biopsy setting in which in situ lesions may be absent. The transcription factor S0X10 labels myoepithelial cells of the breast and salivary glands with corresponding labelling in a subset of breast and salivary gland neoplasms with myoepithelial or basal cell like differentiation. S0X10 rarely labels ER+ BrCa but labels 66–74% of TNBrCa and can be useful even when GATA3 labelling is negative. S0X10 displays nuclear labelling. Peripheral nerve Schwann cells can serve as positive internal controls. However, the main diagnostic pitfall is metastatic melanoma. TRPS1 (trichorhinophalangeal syndrome type 1 is a novel biomarker to aid in the identification of ER+, HER2+ BrCa, TNBrCa and differentiation of invasive BrCa and metastatic BrCa (TRPS1+) from carcinomas of urothelial origin and other origins such as pulmonary, Gl, pancreas etc. (TRPS1-). It is very useful in the differentiation between TNBrCa from melanoma (TRPS1-).




Cytokeratin 5

Cat. No: Mob361, Mob361-01, Mob361-05, PDM139

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: XM26

Cytokeratin 5 immunostaining on breast carcinoma. About 15%-20% of breast carcinoma are characterized with no expression of ER, PR, Her2/neu(c-erbB-2/Oncoprotein) and referred to as TNBrCa or basal like breast carcinoma. Note: Cytokeratin 5 IHC labels this TNBrCa in a diffuse cytoplasmic staining pattern with a perinuclear enhancement.




Cytokeratin 14

Cat. No: Mob186, Mob186-01, Mob186-05, PDM138

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: LL002

Cytokeratin 14 immunostaining on breast carcinoma. About 15%-20% of breast carcinoma are characterized with no expression of ER, PR, Her2/neu(c-erbB-2/Oncoprotein) and referred to as TNBrCa or basal like breast carcinoma. Note: Cytokeratin 14 IHC labels this TNBrCa in a diffuse cytoplasmic staining pattern with a perinuclear enhancement.




EGFR

Cat. No: Mob461, Mob461-01, Mob461-05, PDM226

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: 31G7

EGFR immunostaining on breast carcinoma. Note: EGFR antibody IHC labels this TNBrCa in a cytoplasmic staining pattern with a perinuclear enhancement.




S0X10

Cat. No: Mob565, Mob565-01, Mob565-05, PDM565

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: 20B7

SOX10 immunostaining on breast carcinoma. Note: SOX10 antibody IHC labels this TNBrCa in a nuclear staining pattern.



TRPS1


Cat. No: RMAB615, RMAB615-01, RMAB615-05, RMPD615

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: EPR16171

TRPS1 immunostaining on breast carcinoma. Note: TRPS1 antibody IHC labels this TNBrCa in a nuclear staining pattern.

The distinction between ductal carcinoma and lobular carcinoma either in situ or invasive is usually based on morphology. However, cases with equivocal histomorphologic features have been encountered. IHC is a usual adjunct for accurate classification and differentiation.




E-Cadherin

Cat. No: Mob550, Mob550-01, Mob550-05, PDM182

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: SPM471

p120 catenin/E-cadherin double staining showing invasive ductal carcinoma with membranous labelling with the antibodies of p120 catenin (red) and E-cadherin (brown).



Beta Catenin (p120 Catenin)


Cat. No: Mob529, Mob529-01, Mob529-05, PDM529

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: DBM15.55

Beta Catenin (p120 Catenin)/E-Cadherin double stain showing benign ducts stained in membranous pattern at the center and invasive lobular carcinoma stained in cytoplasm at periphery generating a targetoid appearance.

Histologically, the hallmark of invasive breast carcinoma is the lack of myoepithelial cells (MECs) which functionally are a hybrid of both smooth muscle ("myo," with contractile property) and epithelial cells (with cadherin-mediated cell-cell junctions). Immunohistochemically MECs express filamentous smooth muscle actin (SMA) and smooth muscle myosin heavy chain (SMMHC), intermediate filaments (the epithelial cytokeratins), and some specific markers such as CD10, p40, p63, etc. These biomarkers are very helpful in the differentiation between malignant invasive breast carcinomas versus benign florid proliferation of ducts or lobules.




Actin Alpha Smooth Muscle (SMA)

Cat. No: Mob001, Mob001-01, Mob001-05, PDM003

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: 1A4

SMA immunostaining on breast tissue. Note: SMA antibody IHC labels myoepithelial cells surrounding the florid proliferated ducts.




Calponin

Cat. No: Mob345, Mob345-01, Mob345-05, PDM219

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: CALP

Calponin immunostaining on breast tissue. Note: Calponin antibody IHC labels myoepithelial cells surrounding the florid proliferated ducts.




p40

Cat. No: RP163, RP163-01, RP163-05, PDR055

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: Rabbit

p40 immunostaining on breast tissue. Note: p40 antibody IHC labels the nuclei of myoepithelial cells surrounding the florid proliferated ducts.




p63

Cat. No: RMAB086, RMAB086-01, RMAB086-05, RMPD086

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: DBR16.1

p63 immunostaining on breast tissue. Note: p63 antibody IHC labels the nuclei of myoepithelial cells surrounding the florid proliferated ducts.



CD10

Cat. No: Mob240, Mob240-01, Mob240-05, PDM107

Pack Size: 1 ml, 0.1 ml, 0.5 ml, 6 ml

Clone: 5606

CD10 immunostaining on breast tissue. Note: CD10 antibody IHC labels myoepithelial cells surrounding the florid proliferated ducts.

Breast Cancer Panel Markers

| Actin Alpha Smooth Muscle (SMA) Mob Mob Mob Mob Alp PDM043 1A4 CA15-3 Mob 549, PDM549 DBMM1 Beta Catenin (p120 Catenin) Mob 529, PDM529 DBM15.55 Calponin-1 Mob Mob 348, PDM219 CALP Cytokeratin 14 Mob 188, PDM138 LL002 Cytokeratin 18 Mob Mob 187, PDM206 E3 Cytokeratin 19 Mob Mob 274, PDM192 A53-B/A2.26 Cytokeratin 19 Mob Mob 33, PDM140 MM26-LL002 Cytokeratin 19 Mob Mob 33, PDM192 A53-B/A2.26 Cytokeratin 19 Mob Mob 343, PDM192 A53-B/A2.26 Cytokeratin 19 Mob Mob 343, PDM192 M53-B/A2.26 Cytokeratin 19 Mob Mob 343, PDM192 M53-B/A2.26 Cytokeratin 19 Mob Mob 343, PDM192 M71-L12/30 M71-L12/30 Cytokeratin 19 Mob Mob 341, PDM123 DF/16 B4 M71-L12/30 | Product Name | Product Type | Cat. No | Clone |
|--|--|--------------|------------------|------------------|
| Beta Catenin (p120 Catenin) Mob529, PDM529 DBM15.55 Calponin-1 Mob345, PDM218 CALP Cytokeratin 14 Mob186, PDM138 LL002 Cytokeratin 17 Mob187, PDM164 DC-10 Cytokeratin 18 Mob187, PDM164 DC-10 Cytokeratin 19 Mob244, PDM192 A538/A2.28 Cytokeratin 5/14 Mob3382, PDM123 D5/18 B4 Cytokeratin 5/6 Mob362, PDM123 D5/18 B4 Cytokeratin 5/6 Mob057, PDM097 OYT-1 L2/30 Cytokeratin 5/8 Mob0583, PDM563 LP1K Cytokeratin 8 Mob0549, PDM173 358 β H11 Cytokeratin 8/18 Mob0549, PDM177 358 β H11 Cytokeratin 8/18 Mob0549, PDM170 5D3 E-Cadherin Mob0560, PDM182 SPM471 E6FR (Epithellal growth factor receptor) Mob189, PDM070 5D3 E1bthellal Membrane antigen Mob0401, PDM204 E29 Estrogen Receptor (ER) Mob0401, PDM204 E29 E5trogen Receptor (ER) Mob0560, PDM601 DBM15.52 GOEIP-15 (Gross | Actin Alpha Smooth Muscle (SMA) | | Mob001, PDM003 | 1A4 |
| Calponin-1 Mob345, PDM219 CALP Cyrokeratin 14 Mob186, PDM138 LL002 Cyrokeratin 17 Mob187, PDM164 DC-10 Cyrokeratin 18 Mob187, PDM164 DC-10 Cyrokeratin 19 Mob274, PDM192 A53-B/A2,26 Cyrokeratin 5/14 Mob233, PDM140 XM26+LL002 Cyrokeratin 7 Mob362, PDM123 D5/16 B4 Cyrokeratin 7 Mob0563, PDM563 LP1K Cyrokeratin 8 Mob563, PDM563 LP1K Cyrokeratin 8/18 Mob054, PDM117 35B B H11 Cyrokeratin 8/18 Mob569, PDM563 LP1K Cyrokeratin 8/18 Mob569, PDM563 LP1K Cyrokeratin 8/18 Mob569, PDM563 SPM471 Ecadherin Mob569, PDM182 SPM471 Egrithelial growth factor receptor) Mob569, PDM182 SPM471 Estrogen Receptor (ER) RMAB001, RMP0001 SP1 Estrogen Receptor (ER) RMAB001, RMP0001 SP1 Estrogen Receptor (ER) RMAB004, RMP008 SP3 Her2/neu (-ertb8-2/0ncoprotein) RMAB004 | CA15-3 | | Mob549, PDM549 | DBMM1 |
| Cytokeratin 14 Mob186, PDM138 LL002 Cytokeratin 17 Mob127, PDM206 E3 Cytokeratin 18 Mob187, PDM164 DC-10 Cytokeratin 19 Mob274, PDM192 A53-B/A2.26 Cytokeratin 5/14 Mob233, PDM140 XM26+LL002 Cytokeratin 5/6 Mob382, PDM123 D5/16 B4 Cytokeratin 7 Mob0563, PDM563 LP1K Cytokeratin 8 Mob563, PDM563 LP1K Cytokeratin 8/18 Mob054, PDM117 358 β H11 Cytokeratin 8/18 Mob189, PDM070 5D3 E Cadherin Mob550, PDM182 SPM471 EFRIF (Epithelial growth factor receptor) Mob461, PDM246 29 Estrogen Receptor (ER) RMAB001, RMPD001 SP1 Estrogen Receptor (ER) RMAB001, RMPD001 SP1 Estrogen Receptor (ER) RMAB001, RMPD001 SP3 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Mob564, PDM564 L50-823 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) RMAB008, RMP0008 SP3 Her2/neu (c-eribB-2/Oncoprotein) RMAB004, RMP0004 SP6 | Beta Catenin (p120 Catenin) | | Mob529, PDM529 | DBM15.55 |
| Cytokeratin 17 Mob127, PDM206 E3 Cytokeratin 18 Mob187, PDM164 DC-10 Cytokeratin 19 Mob274, PDM192 A53-B/A2.26 Cytokeratin 5/14 Mob382, PDM123 D5/16 B4 Cytokeratin 5/6 Mob382, PDM123 D5/16 B4 Cytokeratin 7 Mob563, PDM503 LP1K Cytokeratin 8 Mob563, PDM503 LP1K Cytokeratin 8/18 Mob563, PDM503 LP1K Cytokeratin 8/18 Mob189, PDM070 5D3 E-Cadherin Mob550, PDM182 SPM471 E6FR (Epithelial growth factor receptor) Mob461, PDM226 3167 Epithelial Membrane antigen Mob401, PDM226 3167 Estrogen Receptor (ER) RMAB001, RMPD001 SP1 Estrogen Receptor (ER) RMAB004, RMPD001 SP1 Estrogen Receptor (ER) RMAB004, PDM564 L50-823 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Mob566, PDM261 DBM15.52 Her2/neu (c-erbB-2/Oncoprotein) RMAB008, RMPD003 Rabbit Ki67 RMAB008, RMPD003 Rabbit | Calponin-1 | | Mob345, PDM219 | CALP |
| Cytokeratin 18 Mob187, PDM164 DC-10 Cytokeratin 19 Mob274, PDM192 A53-B/A2.26 Cytokeratin 5/14 Mob362, PDM123 D5/16 B4 Cytokeratin 7 Mob057, PDM097 OV-TL 12/30 Cytokeratin 7 Mob563, PDM563 LP1K Cytokeratin 8 Mob054, PDM117 35B β H11 Cytokeratin 8/18 Mob189, PDM070 5D3 E-Cadherin Mob550, PDM182 SPM471 EGFR (Epithelial growth factor receptor) Mob 461, PDM226 3167 Epithelial Membrane antigen Mob401, PDM204 E29 Estrogen Receptor (ER) RMAB001, RMP0001 SP1 Estrogen Receptor (ER) RMAB001, RMP0001 SP1 Estrogen Receptor (ER) Mob564, PDM564 L50-823 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Mob564, PDM564 L50-823 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) RMAB008, RMP0008 SP3 Her2/neu (c-ertb8-2/Oncoprotein) RMAB008, RMP0003 Rabbit Ki67 RMAB004, RMP0004 SP6 Mammaglobin A PDM544 304-1A5 | Cytokeratin 14 | | Mob186, PDM138 | LL002 |
| Cytokeratin 19 Mob274, PDM192 A53-B/A2.26 Cytokeratin 5/14 Mob433, PDM140 XM26+LL002 Cytokeratin 5/6 Mob362, PDM123 D5/16 B4 Cytokeratin 7 Mob057, PDM097 OV-TL 12/30 Cytokeratin 7 Mob563, PDM563 LP1K Cytokeratin 8 Mob054, PDM117 35B β H11 Cytokeratin 8/18 Mob189, PDM070 5D3 E-Cadherin Mob550, PDM182 SPM471 E6FR (Epithelial growth factor receptor) Mob 461, PDM226 3167 Epithelial Membrane antigen Mob401, PDM204 E29 Estrogen Receptor (ER) RMAB001, RMPD001 SP1 Estrogen Receptor (ER) RMAB001, RMPD001 SP1 Estrogen Receptor (ER) Mob564, PDM564 L50-823 GODFP-15 (Gross Cystic Disease Fluid Protein-15) Mob569, PDM261 DBM15.52 Her2/neu (c-erbB-2/Oncoprotein) RMAB008, RMPD008 SP3 Her2/neu (c-erbB-2/Oncoprotein) RMAB004, RMPD004 SP6 Mammaglobin A PDM544 304-1A5 p53 Mob268, PDR055 Rabbit <td>Cytokeratin 17</td> <td></td> <td>Mob127, PDM206</td> <td>E3</td> | Cytokeratin 17 | | Mob127, PDM206 | E3 |
| Cytokeratin 5/14 Mob33, PDM140 XM26+LL002 Cytokeratin 7/6 Mob362, PDM123 D5/16 B4 Cytokeratin 7 Mob057, PDM097 OV-TL 12/30 Cytokeratin 7 Mob563, PDM563 LP1K Cytokeratin 8 Mob054, PDM117 35B β H11 Cytokeratin 8/18 Mob189, PDM070 5D3 E-Cadherin Mob550, PDM182 SPM471 EGFR (Epithelial growth factor receptor) Mob 461, PDM226 31G7 Epithelial Membrane antigen Mob401, PDM204 E29 Estrogen Receptor (ER) RMAB001, RMP0001 SP1 Estrogen Receptor (ER) PDM048, Mob121 GF11 GATA3 Mob564, PDM564 L50-823 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Mob569, PDM261 DBM15.52 Her2/neu (c-erb8-2/Oncoprotein) RMAB008, RMP0008 SP3 Her2/neu (c-erb8-2/Oncoprotein) RP006, PDR003 Rabbit Ki67 RMAB004, RMP0004 SP6 Mammaglobin A PDM544 304-1A5 p40 RP163, PDR055 Rabbit p63 | Cytokeratin 18 | | Mob187, PDM164 | DC-10 |
| Cytokeratin 5/6 Mob362, PDM123 D5/16 B4 Cytokeratin 7 Mob567, PDM097 OV-TL 12/30 Cytokeratin 7 Mob563, PDM563 LP1K Cytokeratin 8 Mob054, PDM117 35B β H11 Cytokeratin 8/18 Mob189, PDM070 5D3 E-Cadherin Mob550, PDM182 SPM471 EGFR (Epithelial growth factor receptor) Mob 461, PDM226 31G7 Epithelial Membrane antigen Mob401, PDM204 E29 Estrogen Receptor (ER) RMAB001, RMPD001 SP1 Estrogen Receptor (ER) PDM048, Mob121 6F11 GATA3 Mob564, PDM564 L50-823 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Mob526, PDM261 DBM15.52 Her2/neu (c-erbB-2/Oncoprotein) RMAB008, RMPD008 SP3 Her2/neu (c-erbB-2/Oncoprotein) RP006, PDR003 Rabbit Ki67 RMAB004, RMPD004 SP6 Mammaglobin A PDM544 304-1A5 p40 RP163, PDR055 Rabbit p53 Mob082, PDM013 D0-7 p63 RMAB008, R | Cytokeratin 19 | | Mob274, PDM192 | A53-B/A2.26 |
| Cytokeratin 7 Mob057, PDM097 OV-TL 12/30 Cytokeratin 7 Mob563, PDM563 LP1K Cytokeratin 8 Mob054, PDM117 35B β H11 Cytokeratin 8/18 Mob189, PDM070 5D3 E-Cadherin Mob550, PDM182 SPM471 EGFR (Epithelial growth factor receptor) Mob 461, PDM226 3167 Epithelial Membrane antigen Mob401, PDM204 E29 Estrogen Receptor (ER) RMAB001, RMPD001 SP1 Estrogen Receptor (ER) PDM048, Mob121 6F11 GATA3 Mob564, PDM564 L50-823 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Mob526, PDM261 DBM15.52 Her2/neu (c-erbB-2/Oncoprotein) RMAB008, RMP0008 SP3 Her2/neu (c-erbB-2/Oncoprotein) RP006, PDR003 Rabbit Ki67 RMAB004, RMPD004 SP6 Mammaglobin A PDM544 304-1A5 p40 RP163, PDR055 Rabbit p63 RMAB007, RMP0086 DBR16.1 Progesteron Receptor (PR) RMAB002, RMP0002 SP2 Smooth muscle myosi | Cytokeratin 5/14 | | Mob433, PDM140 | XM26+LL002 |
| Cytokeratin 7 Mob563, PDM563 LP1K Cytokeratin 8 Mob054, PDM117 358 β H11 Cytokeratin 8/18 Mob189, PDM070 5D3 E-Cadherin Mob550, PDM182 SPM471 EGFR (Epithelial growth factor receptor) Mob 461, PDM226 3167 Epithelial Membrane antigen Mob401, PDM204 E29 Estrogen Receptor (ER) RMAB001, RMPD001 SP1 Estrogen Receptor (ER) PDM048, Mob121 6F11 GATA3 Mob564, PDM564 L50-823 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Mob526, PDM261 DBM15.52 Her2/neu (c-erbB-2/Oncoprotein) RMAB008, RMPD008 SP3 Her2/neu (c-erbB-2/Oncoprotein) RP006, PDR003 Rabbit Ki67 RMAB004, RMPD004 SP6 Mammaglobin A PDM544 304-185 p40 RP163, PDR055 Rabbit p53 RMAB008, RMPD086 DBR16.1 Progesteron Receptor (PR) RMAB092, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 | Cytokeratin 5/6 | | Mob362, PDM123 | D5/16 B4 |
| Cytokeratin 8 Mob054, PDM117 35B β H11 Cytokeratin 8/18 Mob189, PDM070 5D3 E-Cadherin Mob550, PDM182 SPM471 EGFR (Epithelial growth factor receptor) Mob 461, PDM226 3167 Epithelial Membrane antigen Mob401, PDM204 E29 Estrogen Receptor (ER) RMAB001, RMPD001 SP1 Estrogen Receptor (ER) PDM048, Mob121 6F11 GATA3 Mob564, PDM564 L50-823 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Mob526, PDM261 DBM15.52 Her2/neu (c-erbB-2/Oncoprotein) RMAB008, RMPD008 SP3 Her2/neu (c-erbB-2/Oncoprotein) RP006, PDR003 Rabbit Ki67 RMAB004, RMPD004 SP6 Mammaglobin A PDM544 304-1A5 p40 RP163, PDR055 Rabbit p53 Mob082, PDM013 D0-7 p63 RMAB002, RMPD086 DBR16.1 Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 SOX10 | Cytokeratin 7 | | Mob057, PDM097 | 0V-TL 12/30 |
| Cytokeratin 8/18 Mob189, PDM070 5D3 E-Cadherin Mob550, PDM182 SPM471 EGFR (Epithelial growth factor receptor) Mob 461, PDM226 3167 Epithelial Membrane antigen Mob401, PDM204 E29 Estrogen Receptor (ER) RMAB001, RMPD001 SP1 Estrogen Receptor (ER) PDM048, Mob121 6F11 GATA3 Mob564, PDM564 L50-823 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Mob526, PDM261 DBM15.52 Her2/neu (c-erbB-2/Oncoprotein) RMAB008, RMPD008 SP3 Her2/neu (c-erbB-2/Oncoprotein) RP006, PDR003 Rabbit Ki67 RMAB004, RMPD004 SP6 Mammaglobin A PDM544 304-1A5 p40 RP163, PDR055 Rabbit p53 Mob082, PDM013 D0-7 p63 RMAB008, RMPD008 DBR16.1 Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob565, PDM565 20B7 S0X10 RMAB077, RMPD077 EP268 | Cytokeratin 7 | | Mob563, PDM563 | LP1K |
| E-Cadherin Mob550, PDM182 SPM471 EGFR (Epithelial growth factor receptor) Mob 461, PDM226 3167 Epithelial Membrane antigen Mob401, PDM204 E29 Estrogen Receptor (ER) RMAB001, RMPD001 SP1 Estrogen Receptor (ER) PDM048, Mob121 6F11 GATA3 Mob564, PDM564 L50-823 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Mob526, PDM261 DBM15.52 Her2/neu (c-erbB-2/Oncoprotein) RMAB008, RMPD008 SP3 Her2/neu (c-erbB-2/Oncoprotein) RP006, PDR003 Rabbit Ki67 RMAB004, RMPD004 SP6 Mammaglobin A PDM544 304-1A5 p40 RP163, PDR055 Rabbit p53 Mob082, PDM013 D0-7 p63 RMAB004, RMPD006 DBR16.1 Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 S0X10 RMAB077, RMPD077 EP268 | Cytokeratin 8 | | Mob054, PDM117 | 35B β H11 |
| EGFR (Epithelial growth factor receptor) Mob 461, PDM226 3167 Epithelial Membrane antigen Mob401, PDM204 E29 Estrogen Receptor (ER) RMAB001, RMPD001 SP1 Estrogen Receptor (ER) PDM048, Mob121 6F11 GATA3 Mob564, PDM564 L50-823 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Mob526, PDM261 DBM15.52 Her2/neu (c-erbB-2/Oncoprotein) RMAB008, RMPD008 SP3 Her2/neu (c-erbB-2/Oncoprotein) RP006, PDR003 Rabbit Ki67 RMAB004, RMPD004 SP6 Mammaglobin A PDM544 304-1A5 p40 RP163, PDR055 Rabbit p53 Mob082, PDM013 D0-7 p63 RMAB086, RMPD086 DBR16.1 Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 S0X10 RMAB077, RMPD077 EP268 | Cytokeratin 8/18 | | Mob189, PDM070 | 5D3 |
| Epithelial Membrane antigen Mob401, PDM204 E29 Estrogen Receptor (ER) RMAB001, RMPD001 SP1 Estrogen Receptor (ER) PDM048, Mob121 6F11 GATA3 Mob564, PDM564 L50-823 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Mob526, PDM261 DBM15.52 Her2/neu (c-erbB-2/Oncoprotein) RMAB008, RMPD008 SP3 Her2/neu (c-erbB-2/Oncoprotein) RP06, PDR003 Rabbit Ki67 RMAB004, RMPD004 SP6 Mammaglobin A PDM544 304-1A5 p40 RP163, PDR055 Rabbit p53 Mob082, PDM013 D0-7 p63 RMAB008, RMPD086 DBR16.1 Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 S0X10 RMAB077, RMPD077 EP268 | E-Cadherin | | Mob550, PDM182 | SPM471 |
| Estrogen Receptor (ER) | EGFR (Epithelial growth factor receptor) | | Mob 461, PDM226 | 31G7 |
| Estrogen Receptor (ER) | Epithelial Membrane antigen | | Mob401, PDM204 | E29 |
| GATA3 Mob564, PDM564 L50-823 GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Mob526, PDM261 DBM15.52 Her2/neu (c-erbB-2/Oncoprotein) RMAB008, RMPD008 SP3 Her2/neu (c-erbB-2/Oncoprotein) RP006, PDR003 Rabbit Ki67 RMAB004, RMPD004 SP6 Mammaglobin A PDM544 304-1A5 p40 RP163, PDR055 Rabbit p53 Mob082, PDM013 D0-7 p63 RMAB086, RMPD086 DBR16.1 Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 S0X10 Mob565, PDM565 20B7 S0X10 RMAB077, RMPD077 EP268 | Estrogen Receptor (ER) | 5 | RMABOO1, RMPDOO1 | SP1 |
| GCDFP-15 (Gross Cystic Disease Fluid Protein-15) Mob526, PDM261 DBM15.52 Her2/neu (c-erbB-2/Oncoprotein) RMAB008, RMPD008 SP3 Her2/neu (c-erbB-2/Oncoprotein) RP006, PDR003 Rabbit Ki67 RMAB004, RMPD004 SP6 Mammaglobin A PDM544 304-1A5 p40 RP163, PDR055 Rabbit p53 Mob082, PDM013 D0-7 p63 RMAB086, RMPD086 DBR16.1 Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 S0X10 Mob565, PDM565 20B7 S0X10 RMAB077, RMPD077 EP268 | Estrogen Receptor (ER) | 1 | PDM048, Mob121 | 6F11 |
| Her2/neu (c-erbB-2/Oncoprotein) RMAB008, RMPD008 SP3 Her2/neu (c-erbB-2/Oncoprotein) RP006, PDR003 Rabbit Ki67 RMAB004, RMPD004 SP6 Mammaglobin A PDM544 304-1A5 p40 RP163, PDR055 Rabbit p53 Mob082, PDM013 D0-7 p63 RMAB086, RMPD086 DBR16.1 Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 S0X10 Mob565, PDM565 20B7 S0X10 RMAB077, RMPD077 EP268 | GATA3 | 19 | Mob564, PDM564 | L50-823 |
| Her2/neu (c-erbB-2/Oncoprotein) RP006, PDR003 Rabbit Ki67 RMAB004, RMPD004 SP6 Mammaglobin A PDM544 304-1A5 p40 RP163, PDR055 Rabbit p53 Mob082, PDM013 D0-7 p63 RMAB086, RMPD086 DBR16.1 Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 S0X10 Mob565, PDM565 20B7 S0X10 RMAB077, RMPD077 EP268 | GCDFP-15 (Gross Cystic Disease Fluid Protein-15) | | Mob526, PDM261 | DBM15.52 |
| Ki67 RMAB004, RMPD004 SP6 Mammaglobin A PDM544 304-1A5 p40 RP163, PDR055 Rabbit p53 Mob082, PDM013 D0-7 p63 RMAB086, RMPD086 DBR16.1 Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 S0X10 Mob565, PDM565 20B7 S0X10 RMAB077, RMPD077 EP268 | Her2/neu (c-erbB-2/0ncoprotein) | 5 | RMABOO8, RMPDOO8 | SP3 |
| Mammaglobin A PDM544 304-1A5 p40 RP163, PDR055 Rabbit p53 Mob082, PDM013 D0-7 p63 RMAB086, RMPD086 DBR16.1 Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 S0X10 Mob565, PDM565 20B7 S0X10 RMAB077, RMPD077 EP268 | Her2/neu (c-erbB-2/Oncoprotein) | | RP006, PDR003 | Rabbit |
| p40 RP163, PDR055 Rabbit p53 Mob082, PDM013 D0-7 p63 RMAB086, RMPD086 DBR16.1 Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 S0X10 Mob565, PDM565 20B7 S0X10 RMAB077, RMPD077 EP268 | Ki67 | 5 | RMABOO4, RMPDOO4 | SP6 |
| p53 Mob082, PDM013 D0-7 p63 RMAB086, RMPD086 DBR16.1 Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 S0X10 Mob565, PDM565 20B7 S0X10 RMAB077, RMPD077 EP268 | Mammaglobin A | 30 | PDM544 | 304-1A5 |
| p63 RMAB086, RMPD086 DBR16.1 Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 S0X10 Mob565, PDM565 20B7 S0X10 RMAB077, RMPD077 EP268 | p40 | | RP163, PDR055 | Rabbit |
| Progesteron Receptor (PR) RMAB002, RMPD002 SP2 Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 S0X10 Mob565, PDM565 20B7 S0X10 RMAB077, RMPD077 EP268 | p53 | 33 | Mob082, PDM013 | D0-7 |
| Smooth muscle myosin (heavy chain), SMMHC Mob467, PDM175 SMMS-1 S0X10 Mob565, PDM565 20B7 S0X10 RMAB077, RMPD077 EP268 | p63 | | RMAB086, RMPD086 | DBR16.1 |
| S0X10 Mob565, PDM565 20B7 S0X10 RMAB077, RMPD077 EP268 | Progesteron Receptor (PR) | 5 | RMAB002, RMPD002 | SP2 |
| S0X10 | Smooth muscle myosin (heavy chain), SMMHC | 30 | Mob467, PDM175 | SMMS-1 |
| | S0X10 | 33 | Mob565, PDM565 | 20B7 |
| TRPS1 | S0X10 | 5 | RMAB077, RMPD077 | EP268 |
| | TRPS1 | 5 | RMAB615, RMPD615 | EPR16171 |









6616 Owens Drive, Pleasanton, CA 94588, USA

Toll-Free (USA) = :+1 (844) 856-3350, customersupport@dbiosys.com



Germany Lake Constance

Cell: +49 7557 929 3915 wolfgang.vogel@dbiosys.com

Mexico

Avenida Aztecas # 95, Casa 4 Colonia Pueblo de los Reyes Alcaldia Coyoacan CDMX, C.P. 04330

Cell: +525535709693 a.herrera@dbiosys.com

India

612, Eden Square St. John's Road Secunderabad - 500003 Tel: 040-40078333

Cell: +91 9958293222 anandam@dbiosys.com

www.dbiosys.com

Canada

32 Lemsford Drive Markham, ON L3S 4H4

Cell: +1 416 219 2035 hosna.mujadidi@dbiosys.com